查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
脂质奈米颗粒製造的全球市场：服务与技术（按脂质奈米颗粒类型、供应分子类型、公司规模、目标治疗领域、最终用户、主要地区）：产业趋势与全球预测（2023-2035） ）
市场调查报告书
商品编码
1398316

脂质奈米颗粒製造的全球市场：服务与技术（按脂质奈米颗粒类型、供应分子类型、公司规模、目标治疗领域、最终用户、主要地区）：产业趋势与全球预测（2023-2035） ）

Lipid Nanoparticle Manufacturing Market: Services & Technologies-Distribution by Type of Lipid Nanoparticle & Molecule Delivered, Company Size, Target Therapeutic Area, End-user, Key Geographical Regions: Industry Trends & Global Forecasts, 2023-2035
出版日期: | 出版商: Roots Analysis | 英文 290 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2023年，全球脂质奈米颗粒製造市场规模将达6.6亿美元，在预测期间（2023-2035年）复合年增长率为11.8%。

近年来，製药业经历了显着扩张，临床前和临床试验中批准或探索的药物数量不断增加就证明了这一点。 然而，药物开发的一个持续障碍在于许多化合物的低水溶性和低生物利用度。 大约 90% 的正在开发的药物和近 40% 的现有药理製剂面临溶解度和渗透性的挑战。 这些问题通常在被吸收之前就离开了身体，从而影响了有效性。 因此，製药公司正在积极寻求解决方案来克服这些障碍。 在提高治疗药物溶解度和生物利用度的各种策略中，类似脂质奈米颗粒（LNP）的脂质赋形剂引起了药物开发商的极大关注。 LNP 被认为是奈米药物输送的多功能平台，因为它们能够封装多种分子并控制药物释放。 随着该领域研究的不断发展，围绕 LNP 在药物传递中的应用的智力资本也在不断增长。

然而，脂质奈米颗粒的生产是一个复杂且成本密集的过程，需要多种专业知识。 因此，製药公司越来越依赖专业的合约製造组织 (CMO)，这些组织拥有必要的技术和专业知识来解决其技术和营运挑战。 透过外包给此类服务供应商，赞助商可以利用创新的 LNP 技术并获得营运灵活性。 考虑到 LNP 的固有优势（小尺寸、多功能特性和可定製表面），基于 LNP 的治疗市场预计在短期内将显着增长。 这种成长反过来将推动预测期内脂质奈米颗粒製造市场的扩大。

本报告分析了全球优质奈米粒子製造（服务和技术）市场，概述了优质奈米粒子、最新市场状况、主要市场促进和限制因素以及整体市场规模趋势。我们调查了前景、按细分市场和地区划分的详细趋势、主要资本交易和业务联盟的近期动向以及主要公司的概况。

市场主要参与者

  • Acuitas Therapeutics
  • Ascendia Pharmaceuticals
  • Avanti Polar Lipids
  • BIOVECTRA
  • CordenPharma
  • Creative Biolabs
  • Curapath
  • Curia
  • Emergent Biosolutions
  • EUROAPI
  • Evonik
  • Formumax Scientific
  • Fresinius Kabi
  • Fujifilm
  • Integrated Nanotherapeutics
  • leon-nanodrugs
  • Matinas BioPharma
  • Merck
  • Pantherna Therapeutics
  • Precision NanoSystems
  • TLC Biosciences

目录

第一章前言

第二章分析方法

第 3 章经济与其他专案特定考量

第 4 章执行摘要

第 5 章简介

  • 分析概述
  • 脂质概述
  • 脂质奈米颗粒概述
  • 与脂质奈米颗粒生产相关的挑战
  • 需要外包脂质奈米颗粒的生产
  • 结论

第 6 章脂质奈米颗粒：服务供应商格局

  • 分析概述
  • 脂质奈米粒子製造：服务提供者列表

第七章脂质奈米颗粒：技术现况

  • 分析概述
  • 脂质奈米颗粒：技术现状
  • 脂质奈米粒子技术：技术开发商名单

第 8 章其他类型的脂质：服务提供者格局

  • 分析概述
  • 其他类型的脂质：服务提供者列表

第九章企业竞争力分析

  • 分析概述
  • 先决条件与关键参数
  • 分析法
  • 脂质奈米颗粒製造服务商：公司竞争力分析

第10章技术竞争力分析

  • 分析概述
  • 先决条件与关键参数
  • 分析法
  • 脂质奈米粒子技术：竞争分析

第十一章公司简介：脂质奈米颗粒服务商

  • 分析概述
  • Curia
  • Emergent BioSolutions
  • EUROAPI
  • Evonik
  • Ardena
  • BIOVECTRA
  • Company Overview
  • Precision NanoSystems

第十二章公司简介：脂质奈米颗粒技术开发商

  • 分析概述
  • Ascendia Pharmaceuticals
  • leon-nanodrugs
  • Pantherna Therapeutics
  • TLC Biosciences
  • Acuitas Therapeutics
  • Integrated Nanotherapeutics
  • Matinas BioPharma

第 13 章公司简介：其他类型的脂质服务提供者

  • 分析概述
  • Avanti Polar Lipids
  • Corden Pharma
  • Fujifilm
  • Merck
  • FormuMax Scientific
  • Creative Biolabs
  • Fresenius Kabi

第 14 章商业伙伴/合作

  • 分析概述
  • 业务伙伴模式
  • 脂质奈米粒子服务与技术：商业联盟与合作列表

第 15 章可能的合作伙伴分析

  • 分析概述
  • 分析法
  • mRNA 药物开发人员：北美潜在的策略伙伴
  • mRNA 药物开发商：欧洲和亚太地区的潜在策略伙伴

第 16 章买还是买：决策架构

  • 分析概述
  • 先决条件与关键参数
  • 脂质奈米粒子服务提供者： "自製还是外购" 决策框架
  • 结论

第十七章产能分析

  • 分析概述
  • 重要假设与分析方法
  • 脂质奈米颗粒的合约製造能力已在世界各地推广

第 18 章市场影响分析：驱动因素、限制、机会、挑战

  • 分析概述
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
  • 结论

第十九章全球脂质奈米颗粒製造市场

  • 分析概述
  • 假设和分析方法
  • 全球脂质奈米颗粒製造市场：过去趋势（2018-2022）与预测（2023-2035）
  • 主要市场细分

第 20 章脂质奈米颗粒製造市场：依脂质奈米颗粒类型划分

  • 分析概述
  • 重要假设与分析方法
  • 脂质奈米颗粒製造市场：依脂质奈米颗粒类型划分（2018年、2023年、2035年）
  • 数据测量与验证

第 21 章脂质奈米颗粒製造市场，依提供的分子类型划分

  • 分析概述
  • 重要假设与分析方法
  • 脂质奈米颗粒製造市场：依供应分子类型划分（2018、2023、2035）
  • 数据测量与验证

第 22 章脂质奈米颗粒製造市场：依公司规模划分

  • 分析概述
  • 重要假设与分析方法
  • 脂质奈米颗粒製造市场：依公司规模划分（2018、2023、2035）
  • 数据测量与验证

第 23 章脂质奈米颗粒製造市场：依目标治疗领域划分

  • 分析概述
  • 重要假设与分析方法
  • 脂质奈米颗粒製造市场：依目标治疗领域划分（2018、2023、2035）
  • 数据测量与验证

第 24 章脂质奈米颗粒製造市场：依最终用户类型划分

  • 分析概述
  • 重要假设与分析方法
  • 脂质奈米颗粒製造市场：依最终使用者类型划分（2018、2023、2035）
  • 数据测量与验证

第25章脂质奈米颗粒製造市场：依主要地区划分

  • 分析概述
  • 重要假设与分析方法
  • 脂质奈米粒子製造市场：依主要地区划分（2018、2023、2035）
  • 数据测量与验证

第26章结论

第 27 章管理考量

  • 分析概述
  • LIPOSOMA
  • BIOVECTRA
  • OZ Biosciences

第 28 章附录 1：表格资料

第29章附录2：公司与组织名单

简介目录
Product Code: RA100461

The global lipid nanoparticle manufacturing market is valued at USD 0.66 billion in 2023 growing at a CAGR of 11.8% during the forecast period 2023-2035.

In recent years, the pharmaceutical industry has experienced significant expansion, evident in the increasing number of drugs undergoing approval or exploration in preclinical studies and clinical trials. However, a persistent hurdle in drug development lies in the poor water solubility and bioavailability of many compounds. Roughly 90% of drugs in development and nearly 40% of existing pharmacological products face challenges regarding solubility or permeability. These issues often lead to premature elimination from the body before they can be absorbed, impacting their effectiveness. Consequently, pharmaceutical firms are actively seeking solutions to overcome these obstacles. Among the various strategies to enhance the solubility and bioavailability of therapeutic agents, lipid nanoparticles (LNPs) and similar lipid-based additives have attracted substantial attention from drug developers. LNPs are recognized as a versatile platform in nanomedicine delivery due to their capacity to encapsulate diverse molecules and offer controlled drug release. As research in this field flourishes, the intellectual capital concerning the use of LNPs in drug delivery has also expanded.

Yet, manufacturing lipid nanoparticles is a complex and cost-intensive process that demands diverse expertise. Thus, pharmaceutical companies increasingly rely on specialized contract manufacturing organizations (CMOs) equipped with the necessary technology and know-how to tackle technical and operational challenges. Outsourcing to such service providers allows sponsors to tap into innovative LNP technologies and gain operational flexibility. Given the inherent advantages of LNPs-small size, multifunctional properties, and customizable surfaces-the market for LNP-based therapeutics is poised for significant growth in the foreseeable future. This growth will consequently drive expansion in the lipid nanoparticle manufacturing market during the projected period.

Key Market Segments:

Type of Lipid Nanoparticle

  • Solid Lipid Nanoparticles
  • Nanostructured Lipid Carriers

Type of Molecule Delivered

  • Nucleic Acids
  • Small Molecules
  • Peptides/ Proteins
  • Others

Company Size

  • Very Large and Large
  • Mid-sized
  • Small

Therapeutic Area

  • Infectious Diseases
  • Oncological Disorders
  • Blood Disorders
  • Rare Diseases
  • Other Disorders

Type of End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Other End-users

Key Geographical Regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • The report studies the lipid nanoparticle manufacturing market based on type of lipid nanoparticle, type of molecule delivered, company size, target therapeutic area, type of end-user and key geographical regions
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to four major regions
  • Comprehensive methodology adopted for the study, encompassing assumptions, methodologies, and quality control measures for accuracy and reliability of findings.
  • Historical trends, currency fluctuations, foreign exchange impact, recession, and inflation measurements shaping the lipid nanoparticle manufacturing market.
  • High-level overview capturing current state and potential evolution of the lipid nanoparticle manufacturing market in the medium to long term.
  • Exploration of lipids, their types, advantages, applications in pharmaceuticals, challenges in formulation, and the rising need for outsourcing manufacturing operations.
  • Evaluation based on establishment year, company size, headquarters location, manufacturing facility location, operational scale, delivered molecule types, therapeutic areas, and additional services offered.
  • Evaluation based on formulation methods, molecule types, compatible dosage forms, administration routes, therapeutic areas, establishment year, company size, headquarters location, business models, and active players.
  • Examination based on establishment year, company size, headquarters location, manufacturing facilities, operational scale, lipid types, product types, additional services offered, and competitiveness analysis.
  • Comparative assessment of lipid nanoparticle contract manufacturing organizations based on company strength, service strength, and the number of manufacturing facilities.
  • Insightful analysis based on developer strength, technology aspects, and applicability in therapeutic areas.
  • Detailed profiles of key players in LNP manufacturing services and technology, featuring company overview, portfolios, recent developments, and future outlook.
  • Examination of partnerships between stakeholders since 2019, based on various parameters and regional distribution of involved companies.
  • Evaluation of mRNA vaccine and therapeutics developers for potential partnerships with lipid nanoparticle manufacturers, considering multiple criteria.
  • Detailed exploration of factors influencing the decision of companies to outsource LNP manufacturing or develop in-house capabilities.
  • Analysis of global installed capacity among LNP contract manufacturers based on company size, operational scale, and geographical distribution.
  • Identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges impacting lipid nanoparticle manufacturing market growth.

Key Benefits of Buying this Report:

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the lipid nanoparticle manufacturing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies:

  • Acuitas Therapeutics
  • Ascendia Pharmaceuticals
  • Avanti Polar Lipids
  • BIOVECTRA
  • CordenPharma
  • Creative Biolabs
  • Curapath
  • Curia
  • Emergent Biosolutions
  • EUROAPI
  • Evonik
  • Formumax Scientific
  • Fresinius Kabi
  • Fujifilm
  • Integrated Nanotherapeutics
  • leon-nanodrugs
  • Matinas BioPharma
  • Merck
  • Pantherna Therapeutics
  • Precision NanoSystems
  • TLC Biosciences

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Inclusions and Exclusions
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Overview of Lipids
  • 5.3 Introduction to Lipid Nanoparticles
    • 5.3.1. Types of Lipid Nanoparticles
      • 5.3.1.1. Solid Lipid Nanoparticles
      • 5.3.1.2. Nanostructured Lipid Carriers
    • 5.3.2. Advantages of Lipid Nanoparticles
    • 5.3.3. Applications of Lipid Nanoparticles in Pharmaceutical Industry
      • 5.3.3.1. Cancer Treatment
      • 5.3.3.2. Gene Therapy
      • 5.3.3.3. Vaccine Development
      • 5.3.3.4. Medical Imaging / Diagnostics
      • 5.3.3.5. Additional Applications
  • 5.4. Challenges Associated with Lipid Nanoparticle Manufacturing
  • 5.5. Need for Outsourcing Lipid Nanoparticle Manufacturing
  • 5.6. Concluding Remarks

6. LIPID NANOPARTICLES: SERVICE PROVIDERS LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Lipid Nanoparticle Manufacturing: List of Service Providers
    • 6.2.1 Analysis by Year of Establishment
    • 6.2.2 Analysis by Company Size
    • 6.2.3 Analysis by Location of Headquarters
    • 6.2.4 Analysis by Company Size and Location of Headquarters
    • 6.2.5 Analysis by Location of Lipid Nanoparticle Manufacturing Facility
    • 6.2.6 Analysis by Scale of Operation
    • 6.2.7 Analysis by Type of Molecule Delivered
    • 6.2.8 Analysis by Therapeutic Area
    • 6.2.9 Analysis by Type of Additional Services Offered

7. LIPID NANOPARTICLES: TECHNOLOGY LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Lipid Nanoparticle: Technology Landscape
    • 7.2.1. Analysis by Type of Formulation Method
    • 7.2.2. Analysis by Type of Molecule Delivered
    • 7.2.3. Analysis by Compatible Dosage Form
    • 7.2.4. Analysis by Routes of Administration
    • 7.2.5. Analysis by Therapeutic Area
  • 7.3. Lipid Nanoparticle Technologies: List of Technology Developers
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
    • 7.3.4. Analysis by Company Size and Location of Headquarters
    • 7.3.5. Analysis by Business Model
    • 7.3.6. Most Active Players: Analysis by Number of Technologies

8. OTHER TYPES OF LIPIDS: SERVICE PROVIDERS LANDSCAPE

  • 8.1. Chapter Overview
  • 8.2. Other Types of Lipids: List of Service Providers
    • 8.2.1 Analysis by Year of Establishment
    • 8.2.2 Analysis by Company Size
    • 8.2.3 Analysis by Location of Headquarters
    • 8.2.4 Analysis by Company Size and Location of Headquarters
    • 8.2.5. Analysis by Location of Manufacturing Facility
    • 8.2.6. Analysis by Scale of Operation
    • 8.2.7 Analysis by Type of Lipid Manufactured
    • 8.2.8. Analysis by Scale of Operation and Type of Lipid Manufactured
    • 8.2.9. Analysis by Type of Product
    • 8.2.10. Analysis by Type of Additional Services Offered
    • 8.2.11. Analysis by Type of Product and Type of Additional Services Offered

9. COMPANY COMPETITIVENESS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Assumptions and Key Parameters
  • 9.3. Methodology
  • 9.4. Lipid Nanoparticle Manufacturing Service Providers: Company Competitiveness Analysis
    • 9.4.1. Company Competitiveness Analysis: Small Players
    • 9.4.2. Company Competitiveness Analysis : Mid-sized Players
    • 9.4.3. Company Competitiveness Analysis : Large and Very Large Players

10. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Assumptions and Key Parameters
  • 10.3. Methodology
  • 10.4. Lipid Nanoparticle Technologies: Competitiveness Analysis
    • 10.4.1. Technology Competitiveness Analysis: Players based in North America
    • 10.4.2. Technology Competitiveness Analysis: Players based in Europe and Asia-Pacific

11. COMPANY PROFILES: SERVICE PROVIDERS OF LIPID NANOPARTICLES

  • 11.1. Chapter Overview
  • 11.2. Curia
    • 11.2.1. Company Overview
    • 11.2.2. Service Portfolio
    • 11.2.3. Recent Developments and Future Outlook
  • 11.3. Emergent BioSolutions
    • 11.3.1. Company Overview
    • 11.3.2. Service Portfolio
    • 11.3.3. Recent Developments and Future Outlook
  • 11.4. EUROAPI
    • 11.4.1. Company Overview
    • 11.4.2. Service Portfolio
    • 11.4.3. Recent Developments and Future Outlook
  • 11.5. Evonik
    • 11.5.1. Company Overview
    • 11.5.2. Service Portfolio
    • 11.5.3. Recent Developments and Future Outlook
  • 11.6. Ardena
    • 11.6.1. Company Overview
    • 11.6.2. Service Portfolio
  • 11.7. BIOVECTRA
  • 117.1. Company Overview
    • 11.7.2. Service Portfolio
  • 11.8. Precision NanoSystems
    • 11.8.1. Company Overview
    • 11.8.2. Service Portfolio

12. COMPANY PROFILES: LIPID NANOPARTICLE TECHNOLOGY DEVELOPERS

  • 12.1. Chapter Overview
  • 12.2. Ascendia Pharmaceuticals
    • 12.2.1. Company Overview
    • 12.2.2. Lipid Nanoparticle Technology Portfolio
    • 12.2.3. Recent Developments and Future Outlook
  • 12.3. leon-nanodrugs
    • 12.3.1. Company Overview
    • 12.3.2. Lipid Nanoparticle Technology Portfolio
    • 12.3.3. Recent Developments and Future Outlook
  • 12.4. Pantherna Therapeutics
    • 12.4.1. Company Overview
    • 12.4.2. Lipid Nanoparticle Technology Portfolio
    • 12.4.3. Recent Developments and Future Outlook
  • 12.5. TLC Biosciences
    • 12.5.1. Company Overview
    • 12.5.2. Lipid Nanoparticle Technology Portfolio
    • 12.5.3. Recent Developments and Future Outlook
  • 12.6. Acuitas Therapeutics
    • 12.6.1. Company Overview
    • 12.6.2. Service Portfolio
  • 12.7. Integrated Nanotherapeutics
    • 12.7.1. Company Overview
    • 12.7.2. Service Portfolio
  • 12.8. Matinas BioPharma
    • 12.8.1. Company Overview
    • 12.8.2. Service Portfolio

13. COMPANY PROFILES: SERVICE PROVIDERS OF OTHER TYPES OF LIPIDS

  • 13.1. Chapter Overview
  • 13.2. Avanti Polar Lipids
    • 13.2.1. Company Overview
    • 13.2.2. Service Portfolio
    • 13.2.3. Recent Developments and Future Outlook
  • 13.3. Corden Pharma
    • 13.3.1. Company Overview
    • 13.3.2. Service Portfolio
    • 13.3.3. Recent Developments and Future Outlook
  • 13.4. Fujifilm
    • 13.4.1. Company Overview
    • 13.4.2. Service Portfolio
    • 13.4.3. Recent Developments and Future Outlook
  • 13.5. Merck
    • 13.5.1. Company Overview
    • 13.5.2. Service Portfolio
    • 13.5.3. Recent Developments and Future Outlook
  • 13.6. FormuMax Scientific
    • 13.6.1. Company Overview
    • 12.6.2. Service Portfolio
  • 13.7. Creative Biolabs
    • 13.7.1. Company Overview
    • 13.7.2. Service Portfolio
  • 13.8. Fresenius Kabi
    • 13.8.1. Company Overview
    • 13.8.2. Service Portfolio

14. PARTNERSHIPS AND COLLABORATIONS

  • 14.1. Chapter Overview
  • 14.2. Partnership Models
  • 14.3. Lipid Nanoparticles Services and Technologies: List of Partnerships and Collaborations
    • 14.3.1. Analysis by Year of Partnership
    • 14.3.2. Analysis by Type of Partnership
    • 14.3.3. Analysis by Year and Type of Partnership
    • 14.3.4. Analysis by Type of Molecule
    • 14.3.5. Analysis by Therapeutic Area
    • 14.3.6. Analysis by Type of Partner
    • 14.3.7. Most Active Players: Analysis by Number of Partnerships
    • 14.3.8. Analysis by Geography
      • 14.3.8.1. Intracontinental and Intercontinental Deals
      • 14.3.8.2. International and Local Deals

15. LIKELY PARTNER ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Methodology
  • 15.2. mRNA Drug Developers: Potential Strategic Partners in North America
  • 15.3. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific

16. MAKE VERSUS BUY DECISION FRAMEWORK

  • 16.1. Chapter Overview
  • 16.2. Assumptions and Key Parameters
  • 16.3. Lipid Nanoparticle Service Providers: Make versus Buy Decision Making Framework
    • 16.3.1. Scenario 1
    • 16.3.2. Scenario 2
    • 16.3.3. Scenario 3
    • 16.3.4. Scenario 4
  • 16.4. Concluding Remarks

17. CAPACITY ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity
    • 17.3.1. Analysis by Range of Installed Capacity
    • 17.3.2. Analysis by Company Size
    • 17.3.3. Analysis by Scale of Operation
    • 17.3.4. Analysis by Location of Manufacturing Facility
      • 17.3.4.1. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
      • 17.3.4.2. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
      • 17.3.4.3. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
    • 17.3.5. Concluding Remarks

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 18.1. Chapter Overview
  • 18.2. Market Drivers
  • 18.3. Market Restraints
  • 18.4. Market Opportunities
  • 18.5. Market Challenges
  • 18.6. Conclusion

19. GLOBAL LIPID NANOPARTICLE MANUFACTURING MARKET

  • 19.1. Chapter Overview
  • 19.2. Assumptions and Methodology
  • 19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 19.3.1. Scenario Analysis
      • 19.3.1.1. Conservative Scenario
      • 19.3.1.2. Optimistic Scenario
  • 19.4. Key Market Segmentations

20. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF LIPID NANOPARTICLE

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle, 2028, 2023 and 2035
    • 20.3.1. Solid Lipid Nanoparticles, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 20.3.2. Nanostructured Lipid Carriers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 20.7. Data Triangulation and Validation

21. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF MOLECULE DELIVERED

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered, 2018, 2023 and 2035
    • 21.3.1. Nucleic Acids, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 21.3.2. Small Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 21.3.3. Peptides / Proteins, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 21.3.4. Other Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.4. Data Triangulation and Validation

22. LIPID NANOPARTICLE MANUFACTURING MARKET, BY COMPANY SIZE

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
    • 22.3.1. Very Large and Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 22.3.2. Mid-sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 22.3.3. Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.4. Data Triangulation and Validation

23. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TARGET THERAPEUTIC AREA

  • 23.1. Chapter Overview
  • 23.2. Key Assumptions and Methodology
  • 23.3. Lipid Nanoparticle Manufacturing Market: Distribution by Target Therapeutic Area, 2018, 2023 and 2035
    • 23.3.1. Infectious Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.2. Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.3. Blood Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.4. Rare Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.5. Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 23.4. Data Triangulation and Validation

24. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF END-USER

  • 24.1. Chapter Overview
  • 24.2. Key Assumptions and Methodology
  • 24.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of End-user, 2018, 2023 and 2035
    • 24.3.1. Pharmaceutical and Biotechnology Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 24.3.2. Academic and Research Institutes, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 24.3.3. Other End-Users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 24.4. Data Triangulation and Validation

25. LIPID NANOPARTICLE MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 25.1. Chapter Overview
  • 25.2. Key Assumptions and Methodology
  • 25.3. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035
    • 25.3.1. North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 25.3.2. Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 25.3.3. Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 25.3.4. Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 25.4. Data Triangulation and Validation

26. CONCLUSION

27. EXECUTIVE INSIGHTS

  • 27.1. Chapter Overview
  • 27.2. LIPOSOMA
    • 27.2.1. Company Snapshot
  • 27.3. BIOVECTRA
    • 27.3.1. Company Snapshot
  • 27.4. OZ Biosciences
    • 27.4.1. Company Snapshot

28. APPENDIX 1: TABULATED DATA

29. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION